, licensed from Pfizer\tSGLT2 inhibitor\tType 2 diabetes\t \tFasiglifam (TAK-875)\tTakeda\tG-protein-coupled receptor (GPCR) 40 agonist\tType 2 diabetes\t \tFIAsp (NN1218)\tNovo Nordisk\tFaster-acting formulation of insulin aspart\tType 1 and 2 diabetes\t \tForxiga  (dapagliflozin)\tBristol Myers Squibb and AstraZeneca\tSGLT2 inhibitor\tOnce-daily tablets for adults with type 2 diabetes\t \tIDegLira (NN9068)\tNovo Nordisk\tCombination drug therapy\tType 2 diabetes\t \tInvokana (canagliflozin)\tJohnson & Johnson\tSGLT2 inhibitor\tOnce-daily tablets for adults with type 2 diabetes\t \tIpragliflozin L-proline (ASP1941)\tAstellas, MSD, and Kotobuki Pharmaceutical\tSGLT2 inhibitor\tType 2 diabetes\t \tLuseogliflozin hydrate (TS-071)\tTaisho Pharmaceutical\tSGLT2 inhibitor\tOnce-daily for type 2 diabetes\t \tLixiLan (lixisenatide+ insulin glargine)\tSanofi; lixisenatide\tCombination drug therapy \tType 2 diabetes\t \tLyxumia  (lixisenatide)\tSanofi; licensed from Zealand Pharma\tGLP-1 agonist\tOnce-daily for type 2 diabetes\t \tLY2605541 (basal insulin peglispro)\tEli Lilly\tBasal insulin analog\tType 1 and 2 diabetes\t \tLY2963016 (new insulin glargine product)\tEli Lilly and Boehringer Ingelheim\tBasal insulin\tType 1 and 2 diabetes\t \tOmarigliptin (MK-3102)\tMerck & Co.\tDPP-4 inhibitor\tOnce-weekly for adults with type 2 diabetes\t \tRyzodeg  (insulin degludec + insulin aspart)\tNovo Nordisk\tSoluble fixed combination of basal insulin with bolus insulin aspart \tOnce-daily for type 1 and 2 diabetes\t \tSemaglutide (NN9535)\tNovo Nordisk\tGLP-1 analog\tOnce-weekly for type 2 diabetes\t \tSYR-472 (trelagliptin succinate)\tTakeda Pharmaceuticals and Furiex Pharmaceuticals\tDPP-4 inhibitor\tOnce-weekly oral treatment for type 2 diabetes\t \tTresiba  (Insulin degludec)\tNovo Nordisk\tOnce-daily basal insulin\tType 1 and 2 diabetes\t \tU300\tSanofi\tInsulin glargine\tType 1 and 2 diabetes\t \t", "sentences": [], "annotations": [], "relations": []}, {"offset": 51293, "infons": {"file": "biomedicines-10-00331-t003.xml", "id": "biomedicines-10-00331-t003", "section_type": "TABLE", "type": "table_caption"}, "text": "List of new anti-diabetic drugs targeting molecular pathways implicated in diabetes and CVD.", "sentences": [], "annotations": [], "relations": []}, {"offset": 51386, "infons": {"file": "biomedicines-10-00331-t003.xml", "id": "biomedicines-10-00331-t003", "section_type": "TABLE", "type": "table", "xml": "<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Targets</th><th align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Mechanism of Action</th><th align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Leads</th><th align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Ref.</th></tr></thead><tbody><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">11beta-HSD1<break/>(hydroxysteroid dehydrogenase)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Blocking cortisol</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">1. INCB13739, MK-0916, <break/>2.